An mRNA processing pathway suppresses metastasis by governing translational control from the nucleus

Albertas Navickas, Hosseinali Asgharian, Juliane Winkler, Lisa Fish, Kristle Garcia, Daniel Markett, Martin Dodel, Bruce Culbertson, Sohit Miglani, Tanvi Joshi, Phi T. Nguyen, Steven Zhang, Nicholas Stevers, Hun‐Way Hwang, Faraz K. Mardakheh, Andrei Goga, Hani GoodarzibioRxiv 2021 · DOI

Abstract

Cancer cells often co-opt post-transcriptional regulatory mechanisms to achieve pathologic expression of gene networks that drive metastasis. Translational control is a major regulatory hub in oncogenesis, however its effects on cancer progression remain poorly understood. To address this, we used ribosome profiling to compare genome-wide translation efficiencies of poorly and highly metastatic breast cancer cells and patient-derived xenografts. We developed novel regression-based methods to analyze ribosome profiling and alternative polyadenylation data, and identified HNRNPC as a translational controller of a specific mRNA regulon. Mechanistically, HNRNPC, in concert with PABPC4, binds near to poly(A) signals, thereby governing the alternative polyadenylation of a set of mRNAs. We found that HNRNPC and PABPC4 are downregulated in highly metastatic cells, which causes HNRNPC-bound mRNAs to undergo 3’ UTR lengthening and subsequently, translational repression. We showed that modulating HNRNPC expression impacts the metastatic capacity of breast cancer cells in xenograft mouse models. We also found that a small molecule, previously shown to induce a distal-to-proximal poly(A) site switching, counteracts the HNRNPC-PABPC4 driven deregulation of alternative polyadenylation and decreases the metastatic lung colonization by breast cancer cells in vivo.

Introduction

Metastasis—the dissemination of cancer cells from a primary tumor to distant organs—remains the leading cause of mortality in cancer patients. While genetic mutations often initiate primary tumorigenesis, the transition to a metastatic state is frequently driven by non-genetic "software" changes. Recent research has increasingly pointed toward post-transcriptional regulation as a critical hub for these changes. Specifically, translational control allows cells to rapidly alter their protein landscape without the need for new transcription. This study investigates a novel regulatory axis where mRNA processing events within the nucleus directly dictate the efficiency of protein synthesis in the cytoplasm, thereby controlling the metastatic potential of breast cancer cells.

Methodological Framework

To map the translational landscape of metastasis, the researchers employed a multi-omic approach centered on Ribosome Profiling (Ribo-seq). This technique provides a global snapshot of translation by sequencing mRNA fragments protected by ribosomes. To analyze this complex data, the team developed two novel computational frameworks:

  • Ribolog: A logistic regression-based tool designed to detect changes in translation efficiency more accurately than standard negative binomial models. Ribolog effectively eliminates biases caused by ribosome "stalling," providing a clearer picture of actual protein production.
  • APAlog: A specialized tool for analyzing Alternative Polyadenylation (APA), the process by which cells select different cleavage sites at the end of an mRNA molecule.

These tools were applied to a variety of models, including the MDA-MB-231 breast cancer cell line, its highly metastatic derivative MDA-LM2, and patient-derived xenografts (PDXs). Findings were further validated using clinical datasets such as METABRIC, TCGA-BRCA, and CPTAC.

The HNRNPC-PABPC4 Axis

The study identified the RNA-binding proteins HNRNPC and PABPC4 as central regulators of a specific metastatic mRNA regulon. In low-metastatic or healthy cells, these proteins bind near polyadenylation signals in the nucleus. This binding forces the cell to use a "proximal" (closer) cut site, resulting in an mRNA with a shorter 3’ Untranslated Region (UTR).

In contrast, highly metastatic cells exhibit a significant downregulation of HNRNPC and PABPC4. The loss of these proteins allows the cell to use "distal" (farther) polyadenylation sites, leading to the production of mRNAs with significantly longer 3’ UTRs.

The "Bait" Effect and Translational Repression

The functional consequence of this 3’ UTR lengthening is the creation of a molecular "bait." These extended tails contain additional binding sites for microRNAs and Argonaute (AGO2) proteins. Once these inhibitory molecules bind to the lengthened UTR in the cytoplasm, they repress the translation of the mRNA, effectively silencing the gene.

A critical target of this pathway is PDLIM5, a known suppressor of cell migration. When HNRNPC levels are low, PDLIM5 mRNA undergoes 3’ UTR lengthening and subsequent translational repression. The resulting loss of PDLIM5 protein removes a major barrier to cancer cell motility and invasion.

Experimental and Clinical Validation

The researchers demonstrated that the HNRNPC pathway is a potent driver of metastasis in vivo:

  • Metastatic Boost: Knocking down HNRNPC in breast cancer cells led to a ten-fold increase in lung colonization in mouse models.
  • Clinical Correlation: Analysis of patient data revealed that low expression of HNRNPC and PABPC4 correlates with advanced tumor stages and significantly worse overall survival rates.
  • Pharmacological Reversal: The study tested a small molecule, T4, known to promote proximal poly(A) site selection. Treatment with T4 effectively bypassed the HNRNPC deficiency, shortening mRNA tails and significantly reducing the ability of metastatic cells to colonize the lungs.

Conclusion

This research reveals a sophisticated "remote control" mechanism where nuclear RNA processing governs cytoplasmic translation to drive cancer progression. By identifying HNRNPC and PABPC4 as gatekeepers of this process, the study highlights a potential therapeutic vulnerability. The success of the small molecule T4 in reversing metastatic phenotypes suggests that targeting the alternative polyadenylation machinery may offer a novel strategy for preventing the spread of breast cancer.

Summary updated

Abstract

Abstract Cancer cells often co-opt post-transcriptional regulatory mechanisms to achieve pathologic expression of gene networks that drive metastasis. Translational control is a major regulatory hub in oncogenesis, however its effects on cancer progression remain poorly understood. To address this, we used ribosome profiling to compare genome-wide translation efficiencies of poorly and highly metastatic breast cancer cells and patient-derived xenografts. We developed novel regression-based methods to analyze ribosome profiling and alternative polyadenylation data, and identified HNRNPC as a translational controller of a specific mRNA regulon. Mechanistically, HNRNPC, in concert with PABPC4, binds near to poly(A) signals, thereby governing the alternative polyadenylation of a set of mRNAs. We found that HNRNPC and PABPC4 are downregulated in highly metastatic cells, which causes HNRNPC-bound mRNAs to undergo 3’ UTR lengthening and subsequently, translational repression. We showed that modulating HNRNPC expression impacts the metastatic capacity of breast cancer cells in xenograft mouse models. We also found that a small molecule, previously shown to induce a distal-to-proximal poly(A) site switching, counteracts the HNRNPC-PABPC4 driven deregulation of alternative polyadenylation and decreases the metastatic lung colonization by breast cancer cells in vivo .
BibTeX
@misc{navickas2021mrna,
  author = {Albertas Navickas and Hosseinali Asgharian and Juliane Winkler and Lisa Fish and Kristle Garcia and Daniel Markett and Martin Dodel and Bruce Culbertson and Sohit Miglani and Tanvi Joshi and Phi T. Nguyen and Steven Zhang and Nicholas Stevers and Hun‐Way Hwang and Faraz K. Mardakheh and Andrei Goga and Hani Goodarzi},
  title = {{An mRNA processing pathway suppresses metastasis by governing translational control from the nucleus}},
  year = {2021},
  doi = {10.1101/2021.10.04.463118},
  howpublished = {bioRxiv},
}
Figure